Validate your target in real humans.
Most drug targets fail because no one checked them against human genetics until the clinic. CohortLayer tests yours against large human cohorts and returns clear, aggregate evidence that replicates across populations and stays current as the science changes.
For biotech, techbio, and translational teams making high-stakes target decisions.
Grounded in research from
Nature · Nature Genetics · JAMA
The wrong target is the most expensive mistake in drug development.
A target that looks right in a model can still fail in humans. By the time that shows up in clinical trials, the cost is years and hundreds of millions. Human genetic evidence is the strongest early signal that a target is real, which is why getting it right early is one of the highest-leverage calls in the pipeline.
Fewer than 1 in 8 drugs entering clinical trials are ever approved. (Wouters et al., JAMA 2020)
You bring the hypothesis. We run the validation.
- 01
Target validation
Does modulating this gene change disease risk in humans, and is it safe? You get effect size, carrier counts, and phenotype signals across the cohort. - 02
Cross-cohort replication
We test your hypothesis in two large cohorts separately and report whether it replicates. Replication is the strongest filter against a false signal. - 03
Continuous monitoring
When a variant is reclassified or a new finding lands, we re-run automatically and tell you what moved. Your target's evidence never sits stale.
Built for the questions other tools leave open.
Cross-cohort by default
A signal in one population may not hold in another. We test in more than one cohort separately and merge only the aggregates. What we report has already survived a second test.
Continuously current
Public evidence updates constantly. We bind it to the cohort continuously and flag what changed, so a target you validated last quarter is re-checked against today's evidence.
Governed data access, aggregate-only
Genetic data is among the most sensitive categories of personal data. We handle it under EU/GDPR-native principles and return aggregates only. Individual records are never re-identified or moved.
Your target stays yours
We work as your technical partner, not a data vendor. Your commercial strategy and the IP in the results stay with you. Each validation is structured as a rigorous scientific collaboration.